biotech · NSCLC Stage IV · Poliomyelitis
BioMarin Pharmaceutical
Biotech Pharmaceutical Co.,
Biotech Pharmaceutical Co is a biotech organization headquartered in CN. Primary therapeutic focus areas include NSCLC Stage IV, Poliomyelitis, Hyperlipidemias, Non-Hodgkin Lymphoma, Hepatocellular Carcinoma (HCC). NovaP
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 40
- Drugs
- 37
- Patents
- 0
Quick answer
Biotech Pharmaceutical Co is a biotech organization headquartered in CN. Primary therapeutic focus areas include NSCLC Stage IV, Poliomyelitis, Hyperlipidemias, Non-Hodgkin Lymphoma, Hepatocellular Carcinoma (HCC). NovaPharmaNews links 40 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (12), phase 3 (10), phase 1 (8).
Company snapshot
Biotech Pharma is a pharmaceutical and medical equipment company, established 2007 in UAE, with the intention to provide support and services to the health care divisions in the Gulf region, our main focus is the advanced and modern technologies and sciences in the field of pharmacy in the world, like Biotechnology, Nanotechnology, Generic Injectable and Heath Robotic pharmacy workflow systems, an
- 40 active pipeline program(s) linked via ClinicalTrials.gov.
- 40 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for BioMarin Pharmaceutical. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech
- trial_data
BioMarin's Strategic Move: Voxzogo Label Expansion Insights
- approval
BioMarin Seeks Approval for Voxzogo in Short Stature Indication
- approval
BioMarin's SWOT Analysis: Competitive Challenges Ahead
- approval
This Week’s Biopharma News: New Approvals, Appeals, and AI
- approval
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
Recent coverage
BioMarin Rare Disease Therapy Fails Phase 3: Key Takeaways for Pharma Teams
BioMarin Pharmaceutical's rare disease therapy failed to show clinical benefit in a Phase 3 trial, triggering a reassessment of R&D strategy and investor confidence. This article covers key takeaways, regulatory implications, and actionable insights for pharma business development and regulatory teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
BioMarin's SWOT Analysis: Competitive Challenges Ahead
This article delves into BioMarin's SWOT analysis, highlighting competitive challenges and implications for investors and pharma teams.
BioMarin's Study Success: Implications for Pharma Expansion
BioMarin Pharmaceutical has achieved a significant milestone in its latest study, potentially expanding the use of its top-selling medicine. This article explores the implications for the pharmaceutical industry.
Top assets
Lead pipeline drugs
- Marketed / approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for BioMarin Pharmaceutical.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for BioMarin Pharmaceutical.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is BioMarin Pharmaceutical?
-
Is BioMarin Pharmaceutical publicly traded?
-
What drugs does BioMarin Pharmaceutical develop or market?
-
What are the latest developments for BioMarin Pharmaceutical?
-
What therapeutic areas does BioMarin Pharmaceutical focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.